Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind randomized, placebo- and active-controlled proof-of-activity study of UR-63325 in allergen-induced allergic rhinitis
2010-021858-20Phase 2Completed
- Sponsor
- Palau Pharma
- Start
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of seliforant in seasonal allergic rhinitis (SAR) (3 arms), sponsored by Palau Pharma. Primary endpoint: Change from screening in nasal and ocular symptom scores after nasal allergen challenge. Started Aug 2010; status: completed.
02
Drugs
seliforant
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on 2010-021858-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021858-20.